drugset / Trial / NCT05394103
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Timeline
- Start
- 2022-08-30
- Primary completion
- 2025-12-30
- Completion
- 2026-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Q901 | Unknown | — | Intravenous |